Famotidine

CLINICAL USE

H2-blocker:Conditions associated with hyperacidity

DOSE IN NORMAL RENAL FUNCTION

20–80 mg dailyZollinger-Ellison syndrome: 80–800 mg daily in divided doses

PHARMACOKINETICS

  • Molecular weight                           :337.4
  • %Protein binding                           :15–20
  • %Excreted unchanged in urine     : 25–30
  • Volume of distribution (L/kg)       :1.1–1.4
  • half-life – normal/ESRD (hrs)      :3/>20

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : 50% of normal dose
  • <10           : 20 mg at night (maximum)

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in GFR <10 mL/min
  • HD                     :Not dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux   :Not dialysed. Dose as in GFR <10 mL/min
  • CAV/VVHD      :Not dialysed. Dose as in GFR=10–20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Antifungals: absorption of itraconazole and ketoconazole reduced
  • Ciclosporin: possibly increased ciclosporin levelsCytotoxics: possibly reduced dasatinib concentration

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia